Acrivon Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
ACRV$1.58-1.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(in thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $36,015 | $29,519 |
| Short-term investments | 91,443 | 98,232 |
| Prepaid expenses and other current assets | 2,234 | 4,344 |
| Total current assets | 129,692 | 132,095 |
| Property and equipment, net | 3,479 | 2,092 |
| Operating lease right-of-use assets | 4,429 | 4,770 |
| Long-term investments | — | 41,881 |
| Restricted cash | 414 | 388 |
| Deferred offering costs | 251 | — |
| Total assets | $138,265 | $181,226 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $5,048 | $904 |
| Accrued expenses and other current liabilities | 7,378 | 4,886 |
| Operating lease liabilities, current | 877 | 726 |
| Total current liabilities | 13,303 | 6,516 |
| Operating lease liabilities, long-term | 3,767 | 4,235 |
| Total liabilities | 17,070 | 10,751 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized as of December 31, 2023 and 2022, respectively; 0 shares issued and outstanding as of December 31, 2023 and 2022. | — | — |
| Common stock, par value $0.001; 500,000,000 shares authorized as of December 31, 2023 and 2022, respectively; 22,522,644 and 21,920,402 shares issued and outstanding as of December 31, 2023 and 2022, respectively. | 23 | 22 |
| Additional paid-in capital | 237,675 | 226,580 |
| Accumulated other comprehensive loss | (83) | (95) |
| Accumulated deficit | (116,420) | (56,032) |
| Total stockholders’ equity | 121,195 | 170,475 |
| Total liabilities and stockholders’ equity | $138,265 | $181,226 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.